全文获取类型
收费全文 | 99625篇 |
免费 | 7083篇 |
国内免费 | 321篇 |
专业分类
耳鼻咽喉 | 1274篇 |
儿科学 | 2534篇 |
妇产科学 | 2306篇 |
基础医学 | 12437篇 |
口腔科学 | 2061篇 |
临床医学 | 9740篇 |
内科学 | 21742篇 |
皮肤病学 | 1065篇 |
神经病学 | 8652篇 |
特种医学 | 3357篇 |
外国民族医学 | 3篇 |
外科学 | 16223篇 |
综合类 | 1401篇 |
现状与发展 | 1篇 |
一般理论 | 75篇 |
预防医学 | 7883篇 |
眼科学 | 2649篇 |
药学 | 6340篇 |
中国医学 | 142篇 |
肿瘤学 | 7144篇 |
出版年
2023年 | 401篇 |
2022年 | 692篇 |
2021年 | 1646篇 |
2020年 | 880篇 |
2019年 | 1586篇 |
2018年 | 1903篇 |
2017年 | 1399篇 |
2016年 | 1552篇 |
2015年 | 1834篇 |
2014年 | 2726篇 |
2013年 | 4318篇 |
2012年 | 6185篇 |
2011年 | 6454篇 |
2010年 | 3618篇 |
2009年 | 3343篇 |
2008年 | 6123篇 |
2007年 | 6815篇 |
2006年 | 6512篇 |
2005年 | 6661篇 |
2004年 | 6495篇 |
2003年 | 6113篇 |
2002年 | 6103篇 |
2001年 | 782篇 |
2000年 | 538篇 |
1999年 | 764篇 |
1998年 | 1281篇 |
1997年 | 1137篇 |
1996年 | 960篇 |
1995年 | 964篇 |
1994年 | 844篇 |
1993年 | 741篇 |
1992年 | 562篇 |
1991年 | 510篇 |
1990年 | 445篇 |
1989年 | 461篇 |
1988年 | 433篇 |
1987年 | 449篇 |
1986年 | 443篇 |
1985年 | 496篇 |
1984年 | 706篇 |
1983年 | 754篇 |
1982年 | 977篇 |
1981年 | 915篇 |
1980年 | 866篇 |
1979年 | 447篇 |
1978年 | 529篇 |
1977年 | 579篇 |
1976年 | 490篇 |
1975年 | 428篇 |
1974年 | 339篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
22.
23.
24.
25.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
26.
27.
Christine E. Marx William T. Trost Lawrence J. Shampine Robert D. Stevens Christine M. Hulette David C. Steffens John F. Ervin Marian I. Butterfield Daniel G. Blazer Mark W. Massing Jeffrey A. Lieberman 《Neuropsychopharmacology》2006,60(12):1287-1294
BACKGROUND: Few data are currently available investigating neurosteroids (NS) in Alzheimer's disease (AD). The NS allopregnanolone may be decreased in serum and plasma in patients with AD, but it is unclear if allopregnanolone is also reduced in brain. Because a number of NS exhibit neuroprotective effects and impact cognitive performance in rodent models, these molecules may be relevant to the pathophysiology of neurodegenerative disorders. We therefore investigated prefrontal cortex (PFC) NS levels in AD. METHODS: Neurosteroid levels (allopregnanolone, pregnenolone, dehydroepiandrosterone [DHEA]) were determined in postmortem PFC in 14 male subjects with AD and 15 cognitively intact male control subjects by gas chromatography/mass spectrometry preceded by high-performance liquid chromatography purification. RESULTS: Subjects with AD exhibit significant reductions in allopregnanolone compared with cognitively intact control subjects (median levels = 2.50 ng/g vs. 5.59 ng/g, respectively; p = .02). Allopregnanolone levels are inversely correlated with neuropathological disease stage (Braak), r = -.49, p = .007. Median DHEA levels are elevated in subjects with AD (p = .01). CONCLUSIONS: Subjects with AD demonstrate significant reductions in PFC allopregnanolone levels, a finding that may be relevant to neuropathological disease stage severity. Neurosteroids may have utility as candidate biomarkers in AD. 相似文献
28.
29.
Hazel B Breitz Richard E Wendt Michael S Stabin Sui Shen William D Erwin Joseph G Rajendran Janet F Eary Lawrence Durack Ebrahim Delpassand William Martin Ruby F Meredith 《Journal of nuclear medicine》2006,47(3):534-542
166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces. This study evaluated pharmacokinetics and radiation-absorbed dose to all organs from this beta-emitting radiopharmaceutical. METHODS: After two 1.1-GBq administrations of 166Ho-DOTMP, data from whole-body counting using a gamma-camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. The radiation-absorbed dose to normal organs was estimated using MIRD methodology, applying residence times and S values for 166Ho. Marrow dose was estimated from measured activity retained after 18 h. The activity to deliver a therapeutic dose of 25 Gy to the marrow was determined. Methods based on region-of-interest (ROI) and whole-body clearance were evaluated to estimate kidney activity, because the radiotracer is rapidly excreted in the urine. The dose to the surface of the bladder wall was estimated using a dynamic bladder model. RESULTS: In clinical practice, gamma-camera methods were more reliable than uptake probe-based methods for whole-body counting. The intrapatient variability of dose calculations was less than 10% between the 2 tracer studies. Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% (mean, 28%). The activity of 166Ho prescribed for therapy ranged from 38 to 67 GBq (1,030-1,810 mCi). After high-dose therapy, the estimates of absorbed dose to the kidney varied from 1.6 to 4 Gy using the whole-body clearance-based method and from 8.3 to 17.3 Gy using the ROI-based method. Bladder dose ranged from 10 to 20 Gy, bone surface dose ranged from 39 to 57 Gy, and doses to other organs were less than 2 Gy for all patients. Repetitive administration had no impact on tracer biodistribution, pharmacokinetics, or organ dose. CONCLUSION: Pharmacokinetics analysis validated gamma-camera whole-body counting of 166Ho as an appropriate approach to assess clearance and to estimate radiation-absorbed dose to normal organs except the kidneys. Quantitative gamma-camera imaging is difficult and requires scatter subtraction because of the multiple energy emissions of 166Ho. Kidney dose estimates were approximately 5-fold higher when the ROI-based method was used rather than the clearance-based model, and neither appeared reliable. In future clinical trials with 166Ho-DOTMP, we recommend that dose estimation based on the methods described here be used for all organs except the kidneys. Assumptions for the kidney dose require further evaluation. 相似文献
30.